Changes in body composition and muscle strength in girls with idiopathic central precocious puberty during gonadotropin-releasing hormone agonist therapy

Zeynep Donbaloğlu; Berna Singin; Ebru Barsal Çetiner; Aynur Bedel; Bilge Aydın Behram; Kürşat Çetin; Hale Tuhan; Mesut Parlak

Makale detayları

Changes in body composition and muscle strength in girls with idiopathic central precocious puberty during gonadotropin-releasing hormone agonist therapy

Yazarlar:

Zeynep Donbaloğlu | Berna Singin | Ebru Barsal Çetiner | Aynur Bedel | Bilge Aydın Behram | Kürşat Çetin | Hale Tuhan | Mesut Parlak

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Çocuk Endokrinolojisi

Dergi:

Journal of Health Sciences and Medicine Vol.8 Issue 1, pp.63-69

Belge Tipi:

Makale

Yayın Tarihi:

12/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001338917

pISSN:

2636-8579

Anahtar kelimeler:

Özet:

 Aims: Our objective is to explore changes in body fat distribution and muscle strength among a cohort of girls with idiopathic central precocious puberty ICPP undergoing the gonadotropin-releasing hormone analogs GnRHa therapy. Methods: A total of 50 patients who were newly diagnosed with ICPP and treated with GnRHa were included in the study. Patients were investigated at baseline, 6th months and 12th months. Results: Body-mass index BMI standard deviation score SDS was similar throughout the treatment duration. The percentage of body fat PBF increased from 24.25.1 at the beginning to 26.35.3 at the 6th month and to 27.75.43 at the 12th month p0.001. While lean body mass LBM increased during the treatment duration p0.001, there was a decrease in the LBM percentage in both the 6th month and 12th month p0.001, p0.005. The change in PBF between 0 and 12 months was significantly higher in the group with PBF97th percentile p, with a median of 2.3 3.3, compared to a median of 0.5 0.5 in the group with PBF97th p p0.005. Conclusion: Over the one-year duration of GnRHa treatment, no increase was observed in BMI SDS. While PBF increased, a decrease was noted in LBM percentage. Despite the decrease in LBM percentage, since LBM increased over the course of treatment, an increase in muscle strength was observed under GnRHa therapy. Additionally, the alteration in PBF during GnRHa treatment exhibited variations based on the initial PBF status.

 Aims: Our objective is to explore changes in body fat distribution and muscle strength among a cohort of girls with idiopathic central precocious puberty ICPP undergoing the gonadotropin-releasing hormone analogs GnRHa therapy. Methods: A total of 50 patients who were newly diagnosed with ICPP and treated with GnRHa were included in the study. Patients were investigated at baseline, 6th months and 12th months. Results: Body-mass index BMI standard deviation score SDS was similar throughout the treatment duration. The percentage of body fat PBF increased from 24.25.1 at the beginning to 26.35.3 at the 6th month and to 27.75.43 at the 12th month p0.001. While lean body mass LBM increased during the treatment duration p0.001, there was a decrease in the LBM percentage in both the 6th month and 12th month p0.001, p0.005. The change in PBF between 0 and 12 months was significantly higher in the group with PBF97th percentile p, with a median of 2.3 3.3, compared to a median of 0.5 0.5 in the group with PBF97th p p0.005. Conclusion: Over the one-year duration of GnRHa treatment, no increase was observed in BMI SDS. While PBF increased, a decrease was noted in LBM percentage. Despite the decrease in LBM percentage, since LBM increased over the course of treatment, an increase in muscle strength was observed under GnRHa therapy. Additionally, the alteration in PBF during GnRHa treatment exhibited variations based on the initial PBF status.

 Aims: Our objective is to explore changes in body fat distribution and muscle strength among a cohort of girls with idiopathic central precocious puberty ICPP undergoing the gonadotropin-releasing hormone analogs GnRHa therapy. Methods: A total of 50 patients who were newly diagnosed with ICPP and treated with GnRHa were included in the study. Patients were investigated at baseline, 6th months and 12th months. Results: Body-mass index BMI standard deviation score SDS was similar throughout the treatment duration. The percentage of body fat PBF increased from 24.25.1 at the beginning to 26.35.3 at the 6th month and to 27.75.43 at the 12th month p0.001. While lean body mass LBM increased during the treatment duration p0.001, there was a decrease in the LBM percentage in both the 6th month and 12th month p0.001, p0.005. The change in PBF between 0 and 12 months was significantly higher in the group with PBF97th percentile p, with a median of 2.3 3.3, compared to a median of 0.5 0.5 in the group with PBF97th p p0.005. Conclusion: Over the one-year duration of GnRHa treatment, no increase was observed in BMI SDS. While PBF increased, a decrease was noted in LBM percentage. Despite the decrease in LBM percentage, since LBM increased over the course of treatment, an increase in muscle strength was observed under GnRHa therapy. Additionally, the alteration in PBF during GnRHa treatment exhibited variations based on the initial PBF status.

 Amaçlar: Amacımız, gonadotropin salgılatıcı hormon analogları GnRHa tedavisi gören idiyopatik santral erken ergenlik ICPP hastası kızlardan oluşan bir kohortta vücut yağ dağılımı ve kas gücündeki değişiklikleri incelemektir. Yöntemler: Çalışmaya yeni ICPP tanısı almış ve GnRHa ile tedavi edilen toplam 50 hasta dahil edildi. Hastalar başlangıçta, 6. ayda ve 12. ayda incelendi. Sonuçlar: Vücut kitle indeksi VKİ standart sapma skoru SDS tedavi süresi boyunca benzerdi. Vücut yağ yüzdesi PBF başlangıçta 24,25,1den 6. ayda 26,35,3e ve 12. ayda 27,75,43e yükseldi p0,001. Tedavi süresi boyunca yağsız vücut kütlesi LBM artarken p0,001, hem 6. ayda hem de 12. ayda LBM yüzdesinde azalma görüldü p0,001, p0,005. 0 ile 12 ay arasındaki PBFdeki değişim, PBF97. persentil olan grupta anlamlı şekilde daha yüksekti p, medyan 2,3 3,3 iken, PBF97. p olan grupta medyan 0,5 0,5 idi p0,005. Sonuç: GnRHa tedavisinin bir yıllık süresi boyunca, BMI SDSde artış gözlenmedi. PBF artarken, LBM yüzdesinde bir azalma kaydedildi. LBM yüzdesindeki azalmaya rağmen, LBM tedavi süresince arttığından, GnRHa tedavisi altında kas gücünde bir artış gözlendi. Ayrıca, GnRHa tedavisi sırasında PBFdeki değişim, başlangıç PBF durumuna bağlı olarak farklılıklar gösterdi.

Makale detayları

Changes in body composition and muscle strength in girls with idiopathic central precocious puberty during gonadotropin-releasing hormone agonist therapy

Yazarlar:

Zeynep Donbaloğlu | Berna Singin | Ebru Barsal Çetiner | Aynur Bedel | Bilge Aydın Behram | Kürşat Çetin | Hale Tuhan | Mesut Parlak

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Çocuk Endokrinolojisi

Dergi:

Journal of Health Sciences and Medicine Vol.8 Issue 1, pp.63-69

Belge Tipi:

Makale

Yayın Tarihi:

12/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001338917

pISSN:

2636-8579

Central precocious puberty

GnRHa therapy

body composition

lean body mass

muscle strengthMerkezi erken ergenlik

GnRHa tedavisi

vücut kompozisyonu

yağsız vücut kütlesi

kas gücü

Sayı

Makale detayları

Yazarlar: Zeynep Donbaloğlu | Berna Singin | Ebru Barsal Çetiner | Aynur Bedel | Bilge Aydın Behram | Kürşat Çetin | Hale Tuhan | Mesut Parlak

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Çocuk Endokrinolojisi

Dergi: Journal of Health Sciences and Medicine Vol.8 Issue 1, pp.63-69

Belge Tipi: Makale

Yayın Tarihi: 12/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001338917

pISSN: 2636-8579

Sayı

Yazarlar:

Zeynep Donbaloğlu | Berna Singin | Ebru Barsal Çetiner | Aynur Bedel | Bilge Aydın Behram | Kürşat Çetin | Hale Tuhan | Mesut Parlak

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Çocuk Endokrinolojisi

Dergi:

Journal of Health Sciences and Medicine Vol.8 Issue 1, pp.63-69

Belge Tipi:

Makale

Yayın Tarihi:

12/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001338917

pISSN:

2636-8579